Alternative ADHD Treatment When Vyvanse (Lisdexamfetamine) Fails
If Vyvanse doesn't work after adequate dosing and duration, switch to methylphenidate as your next stimulant option before considering non-stimulants. 1
Algorithmic Approach to Treatment Selection
Step 1: Verify Adequate Vyvanse Trial
Before switching medications, confirm:
- Dosing: Titrated up to 70 mg/day (maximum dose) 2
- Duration: At least 4-6 weeks at therapeutic dose
- Adherence: Patient actually taking medication consistently
- Timing: Taken in morning as prescribed
Step 2: Switch to Alternative Stimulant First
Methylphenidate should be your next choice - this is explicitly recommended by guidelines when lisdexamfetamine fails 1. The rationale is straightforward: stimulants have the largest effect sizes for ADHD symptom reduction, and patients who don't respond to one stimulant class (amphetamines like Vyvanse) may respond to another (methylphenidate) 1.
Methylphenidate options include:
- Extended-release formulations for once-daily dosing (preferred for adherence) 1
- Various delivery systems (oral tablets, chewable, transdermal patches) to individualize treatment 1
- Titrate to maximum benefit with tolerable side effects 3
Step 3: Consider Non-Stimulants Only After Stimulant Failure
Non-stimulants are second-line therapy because they have smaller effect sizes than stimulants 1. However, they become appropriate when:
- Both amphetamine and methylphenidate classes have failed
- Stimulants cause intolerable side effects
- Patient has comorbid conditions where non-stimulants may be preferred (see below)
- Concerns about stimulant diversion or substance use disorder exist
Non-Stimulant Options (Ranked by Evidence)
First-Tier Non-Stimulants:
1. Atomoxetine (Strattera)
- Mechanism: Norepinephrine reuptake inhibitor 1
- Dosing: Start 0.5 mg/kg/day, titrate to 1.2-1.4 mg/kg/day (max 100 mg/day) 1
- Timeline: Requires 6-12 weeks to see full effect 1
- Advantages: Around-the-clock coverage, non-controlled substance, may help with comorbid anxiety 1
- Critical monitoring: Black box warning for suicidal ideation in children/adolescents - monitor closely especially first few months 1
2. Guanfacine Extended-Release (Intuniv)
- Mechanism: Alpha-2 adrenergic agonist 1
- Dosing: Weight-based, approximately 0.1 mg/kg once daily, available in 1-4 mg tablets 1
- Timeline: 2-4 weeks until effects observed 1
- Advantages: Once-daily dosing, helpful for comorbid tics/Tourette's, sleep problems, aggression 1
- Key side effect: Somnolence/sedation - dose at bedtime 1
3. Clonidine Extended-Release (Kapvay)
- Mechanism: Alpha-2 adrenergic agonist 1
- Dosing: Start 0.1 mg at bedtime, can increase to twice daily, max 0.4 mg/day 1
- Timeline: 2-4 weeks until effects observed 1
- Disadvantage: Requires twice-daily dosing (less convenient than guanfacine) 1
- Transdermal patch available for patients who can't swallow pills 1
Second-Tier Non-Stimulants (Off-Label):
4. Viloxazine Extended-Release
- Newer norepinephrine reuptake inhibitor
- Emerging evidence in adults 4, 5
- Consider if atomoxetine not tolerated
5. Bupropion
- Norepinephrine and dopamine reuptake inhibitor
- More effective than placebo but less studied than above options 4, 6
- May help with comorbid depression
- Avoid if seizure history
Special Considerations by Comorbidity
Prioritize non-stimulants as FIRST-LINE (before trying stimulants) if patient has:
- Substance use disorder: Atomoxetine, guanfacine, or clonidine (non-controlled) 1
- Tic disorder/Tourette's syndrome: Guanfacine or clonidine 1
- Severe anxiety: Atomoxetine or alpha-2 agonists 1
- Disruptive behavior disorders: Alpha-2 agonists 1
- Sleep disturbances: Guanfacine or clonidine (sedating effects beneficial) 1
Augmentation Strategy
If partial response to stimulants, consider adding (not switching):
- Guanfacine or clonidine can be added to stimulants 1
- FDA-approved as adjunctive therapy in US 1
- May reduce stimulant side effects (sleep problems, cardiovascular effects) 1
Critical Pitfalls to Avoid
Don't give up on stimulants too early - try both amphetamine AND methylphenidate classes before declaring stimulant failure 1
Don't expect rapid results with non-stimulants - atomoxetine takes 6-12 weeks, alpha-2 agonists take 2-4 weeks 1. Patients expecting stimulant-like immediate effects will be disappointed.
Monitor suicidality with atomoxetine - especially in children/adolescents during first months and dose changes 1
Watch for sedation with alpha-2 agonists - dose at bedtime initially, warn about driving/operating machinery 1
Don't abruptly stop alpha-2 agonists - risk of rebound hypertension 1
Screen for cardiac disease before ANY ADHD medication - both stimulants and non-stimulants affect cardiovascular parameters 3, 2
Monitoring Parameters
For all ADHD medications:
- Blood pressure and heart rate at each visit 1
- Height and weight (growth suppression concern) 1
- ADHD symptom scales to assess response
- Side effects and tolerability
Additional for atomoxetine: